Evidence map›Paper›PMID 26233703›Full record

ArticleRedox biology2015

Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.

A Rodríguez-Hernández, E Navarro-Villarán, R González, S Pereira, L B Soriano-De Castro, A Sarrias-Giménez, L Barrera-Pulido, J M Álamo-Martínez, A Serrablo-Requejo, G Blanco-Fernández and 13 more

Erratum issuedAbstract read
In one paragraph

Article in Redox biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. S-nitrosothiols and HRedox biology · 2019
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

A Rodríguez-HernándezInstitute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
E Navarro-VillaránInstitute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
R GonzálezDepartament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain.
S PereiraInstitute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
L B Soriano-De CastroInstitute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
A Sarrias-GiménezInstitute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
L Barrera-PulidoDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
J M Álamo-MartínezDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
A Serrablo-RequejoHepato-Biliary Surgery Unit, Hospital Universitario "Miguel Servet", Zaragoza, Spain.
G Blanco-FernándezHepato-Biliary-Pancreatic and Liver Transplant Service, Hospital Universitario "Infanta Cristina", Badajoz, Spain.
A Nogales-MuñozDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
A Gila-BohórquezDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
D PachecoDepartment of General Surgery and Department of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain.
M A Torres-NietoDepartment of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain.
J Serrano-Díaz-CanedoDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
G Suárez-ArtachoDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
C Bernal-BellidoDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
L M Marín-GómezDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
J A BarcenaDepartament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain.
M A Gómez-BravoDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
C A PadillaDepartament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain.
F J PadilloDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
J MuntanéDepartment of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain. Electronic address: jmuntane-ibis@us.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitric oxide (NO) plays a relevant role during cell death regulation in tumor cells. The overexpression of nitric oxide synthase type III (NOS-3) induces oxidative and nitrosative stress, p53 and cell death receptor expression and apoptosis in hepatoblastoma cells. S-nitrosylation of cell death receptor modulates apoptosis. Sorafenib is the unique recommended molecular-targeted drug for the treatment of patients with advanced hepatocellular carcinoma. The present study was addressed to elucidate the potential role of NO during Sorafenib-induced cell death in HepG2 cells. We determined the intra- and extracellular NO concentration, cell death receptor expression and their S-nitrosylation modifications, and apoptotic signaling in Sorafenib-treated HepG2 cells. The effect of NO donors on above parameters has also been determined. Sorafenib induced apoptosis in HepG2 cells. However, low concentration of the drug (10nM) increased cell death receptor expression, as well as caspase-8 and -9 activation, but without activation of downstream apoptotic markers. In contrast, Sorafenib (10 µM) reduced upstream apoptotic parameters but increased caspase-3 activation and DNA fragmentation in HepG2 cells. The shift of cell death signaling pathway was associated with a reduction of S-nitrosylation of cell death receptors in Sorafenib-treated cells. The administration of NO donors increased S-nitrosylation of cell death receptors and overall induction of cell death markers in control and Sorafenib-treated cells. In conclusion, Sorafenib induced alteration of cell death receptor S-nitrosylation status which may have a relevant repercussion on cell death signaling in hepatoblastoma cells.

Indexed as

Gene Expression Regulation, NeoplasticSignal TransductionAntineoplastic AgentsCaspase 3Caspase 8Caspase 9Cell DeathCysteineHep G2 CellsHumansNiacinamideNitric OxideNitric Oxide DonorsNitric Oxide Synthase Type IIIPhenylurea CompoundsReceptors, TNF-Related Apoptosis-Inducing LigandAntineoplastic AgentsCASP3 protein, humanCASP8 protein, humanCASP9 protein, humanCaspase 3Caspase 8Caspase 9CysteineNiacinamideNitric OxideNitric Oxide DonorsNitric Oxide Synthase Type IIINOS3 protein, humanPhenylurea CompoundsReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Tumor Necrosis Factor, Type IS-nitrosocysteineS-NitrosothiolsSorafenibApoptosisDeath-receptorsHepatoblastomaNOS-nitrosylationSorafenib

Identifiers

PMID26233703
PMCPMC4534573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.